Literature DB >> 9648595

Cervical cancer with paraaortic metastases: significance of residual paraaortic disease after surgical staging.

P Y Kim1, B J Monk, S Chabra, R A Burger, S A Vasilev, A Manetta, P J DiSaia, M L Berman.   

Abstract

Cervical carcinoma frequently metastasizes to the paraaortic region, necessitating extended field radiotherapy to effect a cure. As imaging modalities are unreliable in identifying all cases of paraaortic nodal metastases (PAN), surgical staging is often utilized prior to radiotherapy. This study was aimed at identifying factors predictive of survival in women with cervical carcinoma and paraaortic metastases. In particular, survival based on extent of paraaortic disease was examined. The study group consisted of 43 women (stages IB-IVB) identified between 1982 and 1993 who were treated with extended field radiation for cervical carcinoma with histologically confirmed paraaortic metastases. The estimated 5-year survival for the study population was 24% with a median survival of 18 months. Pelvic tumor size had a significant impact on survival with the median survival being 34 months if the primary lesion was < 6 cm compared to 14 months if > or = 6 cm (P = 0.01). Eight of the 26 (31%) women without residual PAN disease after surgical staging remain alive and disease free (mean follow-up, 74 months). In contrast, only 1 of the 17 (6%) women with gross residual PAN is alive 71 months after treatment (P = 0.05). However, a comparison of Kaplan-Meier survival curves did not show a statistically significant advantage to the surgical excision of grossly involved PAN (P = 0.98). Although long-term survival among women with grossly involved, unresected paraaortic metastases is uncommon, further study is necessary to elucidate the role of surgical excision of bulky aortic disease in women with cervical cancer.

Entities:  

Mesh:

Year:  1998        PMID: 9648595     DOI: 10.1006/gyno.1998.5012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Survival benefit of laparoscopic surgical staging-guided radiation therapy in locally advanced cervical cancer.

Authors:  Dae Gy Hong; Nae Yoon Park; Gun Oh Chong; Young Lae Cho; Il Soo Park; Yoon Soon Lee
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Experiences of pretreatment laparoscopic surgical staging in patients with locally advanced cervical cancer: results of a prospective study.

Authors:  Myong Cheol Lim; Jaeman Bae; Jeong-Yoel Park; Soyi Lim; Sokbom Kang; Sang-Soo Seo; Joo-Yong Kim; Ju-Won Rho; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

3.  Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study.

Authors:  Donald G Mitchell; Bradley Snyder; Fergus Coakley; Caroline Reinhold; Gillian Thomas; Marco A Amendola; Lawrence H Schwartz; Paula Woodward; Harpreet Pannu; Mostafa Atri; Hedvig Hricak
Journal:  Gynecol Oncol       Date:  2008-11-20       Impact factor: 5.482

4.  Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer.

Authors:  Koji Matsuo; Muneaki Shimada; Tsuyoshi Saito; Kazuhiro Takehara; Hideki Tokunaga; Yoh Watanabe; Yukiharu Todo; Ken Ichirou Morishige; Mikio Mikami; Toru Sugiyama
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

5.  Laparoscopic transperitoneal infrarenal para-aortic lymphadenectomy in patients with FIGO stage IB1-II B cervical carcinoma.

Authors:  Dae G Hong; Nae Y Park; Gun O Chong; Young L Cho; Il S Park; Yoon S Lee; Dae Hyung Lee
Journal:  JSLS       Date:  2012 Apr-Jun       Impact factor: 2.172

6.  Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis.

Authors:  Szu-Yuan Wu; Eng-Yen Huang; Chan-Chao Chanchien; Hao Lin; Chong-Jong Wang; Li-Min Sun; Hui-Chun Chen; Fu-Min Fang; Hsuan-Chih Hsu; Yu-Jie Huang
Journal:  J Radiat Res       Date:  2013-06-27       Impact factor: 2.724

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.